Advertisement
OCUL vs WVE
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OCUL is a Hold and WVE is a Hold.
OCUL's RSI Indicator climbs out of oversold territory
The RSI Indicator for OCUL moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 37 similar instances when the indicator left oversold territory. In 34 of the 37 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 61 cases where OCUL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for OCUL just turned positive on October 23, 2026. Looking at past instances where OCUL's MACD turned positive, the stock continued to rise in 40 of 51 cases over the following month. The odds of a continued upward trend are 78%.
Following a +6.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where OCUL advanced for three days, in 202 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
OCUL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OCUL as a result. In 68 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The 50-day moving average for OCUL moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OCUL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for OCUL entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.785) is normal, around the industry mean (3.498). P/E Ratio (-4.711) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (40.650) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. OCUL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OCUL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
WVE's RSI Oscillator ascends from oversold territory
The RSI Indicator for WVE moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 22 similar instances when the indicator left oversold territory. In 19 of the 22 cases the stock moved higher. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 67 cases where WVE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for WVE just turned positive on October 19, 2026. Looking at past instances where WVE's MACD turned positive, the stock continued to rise in 44 of 55 cases over the following month. The odds of a continued upward trend are 80%.
Following a +8.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where WVE advanced for three days, in 206 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on WVE as a result. In 71 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WVE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
WVE broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for WVE entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.462) is normal, around the industry mean (3.498). P/E Ratio (-3.116) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (12.953) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. WVE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WVE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
OCUL | WVE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 15 | 21 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 30 Undervalued | 30 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 78 | 79 | |
P/E GROWTH RATING 1..100 | 18 | 12 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
OCUL's Valuation (30) in the Pharmaceuticals Other industry is in the same range as WVE (30) in the Biotechnology industry. This means that OCUL’s stock grew similarly to WVE’s over the last 12 months.
OCUL's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as WVE (100) in the Biotechnology industry. This means that OCUL’s stock grew similarly to WVE’s over the last 12 months.
OCUL's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as WVE (98) in the Biotechnology industry. This means that OCUL’s stock grew similarly to WVE’s over the last 12 months.
OCUL's Price Growth Rating (78) in the Pharmaceuticals Other industry is in the same range as WVE (79) in the Biotechnology industry. This means that OCUL’s stock grew similarly to WVE’s over the last 12 months.
WVE's P/E Growth Rating (12) in the Biotechnology industry is in the same range as OCUL (18) in the Pharmaceuticals Other industry. This means that WVE’s stock grew similarly to OCUL’s over the last 12 months.
| OCUL | WVE | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 86% |
| Stochastic ODDS (%) | 1 day ago 79% | 1 day ago 79% |
| Momentum ODDS (%) | 1 day ago 78% | 1 day ago 89% |
| MACD ODDS (%) | 1 day ago 78% | 1 day ago 80% |
| TrendWeek ODDS (%) | 1 day ago 82% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 81% | 1 day ago 80% |
| Advances ODDS (%) | 3 days ago 80% | 3 days ago 76% |
| Declines ODDS (%) | 10 days ago 83% | 10 days ago 86% |
| BollingerBands ODDS (%) | 1 day ago 78% | 1 day ago 89% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
OCUL’s FA Score shows that 2 FA rating(s) are green while WVE’s FA Score has 2 green FA rating(s).
- OCUL’s FA Score: 2 green, 3 red.
- WVE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
OCUL’s TA Score shows that 5 TA indicator(s) are bullish while WVE’s TA Score has 4 bullish TA indicator(s).
- OCUL’s TA Score: 5 bullish, 4 bearish.
- WVE’s TA Score: 4 bullish, 4 bearish.
Price Growth
OCUL (@Biotechnology) experienced а -6.72% price change this week, while WVE (@Biotechnology) price change was -5.52% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
OCUL is expected to report earnings on Mar 08, 2027.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
OCUL and
Correlation & Price change
A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with AMLX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then AMLX could also see price increases.
| Ticker / NAME | Correlation To OCUL | 1D Price Change % | ||
|---|---|---|---|---|
| OCUL | 100% | +0.76% | ||
| AMLX - OCUL | 47% Loosely correlated | +2.88% | ||
| KYMR - OCUL | 44% Loosely correlated | -1.32% | ||
| GPCR - OCUL | 43% Loosely correlated | -3.59% | ||
| WVE - OCUL | 42% Loosely correlated | +0.29% | ||
| REPL - OCUL | 37% Loosely correlated | -6.44% | ||
More | ||||
WVE and
Correlation & Price change
A.I.dvisor indicates that over the last year, WVE has been loosely correlated with GPCR. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if WVE jumps, then GPCR could also see price increases.
| Ticker / NAME | Correlation To WVE | 1D Price Change % | ||
|---|---|---|---|---|
| WVE | 100% | +0.29% | ||
| GPCR - WVE | 64% Loosely correlated | -3.59% | ||
| KYMR - WVE | 53% Loosely correlated | -1.32% | ||
| IBIO - WVE | 52% Loosely correlated | +5.67% | ||
| FRMM - WVE | 44% Loosely correlated | +4.61% | ||
| OCUL - WVE | 41% Loosely correlated | +0.76% | ||
More | ||||